Evidence map›Paper›PMID 30002119›Full record

ArticleEMBO reports2018

Deletion of

Jean-François De Backer, Stéphanie Monlezun, Bérangère Detraux, Adeline Gazan, Laura Vanopdenbosch, Julian Cheron, Giuseppe Cannazza, Sébastien Valverde, Lídia Cantacorps, Mérie Nassar and 8 more

Open access · greenAbstract read
In one paragraph

Article in EMBO reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Drug addiction: from bench to bedside.Translational psychiatry · 2021
    Review
  6. Article
  7. Review
  8. GPRIN3 Controls Neuronal Excitability, Morphology, and Striatal-Dependent Behaviors in the Indirect Pathway of the Striatum.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019
    Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 4 countries.

Jean-François De BackerLaboratoire de Neurophysiologie, ULB Neuroscience Institute, Université Libre de Bruxelles (ULB), Brussels, Belgium.ORCID 0000-0002-2861-9994
Stéphanie MonlezunLaboratoire de Neurophysiologie, ULB Neuroscience Institute, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Bérangère DetrauxLaboratoire de Neurophysiologie, ULB Neuroscience Institute, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Adeline GazanLaboratoire de Neurophysiologie, ULB Neuroscience Institute, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Laura VanopdenboschLaboratoire de Neurophysiologie, ULB Neuroscience Institute, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Julian CheronLaboratoire de Neurophysiologie, ULB Neuroscience Institute, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Giuseppe CannazzaDipartimento di Scienze della Vita, Centro di Neuroscienze e Neurotecnologie, Università degli Studi di Modena e Reggio Emilia, Modena, Italy.
Sébastien ValverdeINSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), UPMC Univ Paris 06 Sorbonne Universités, Paris, France.
Lídia CantacorpsDepartament de Ciències Experimentals i de la Salut, Grup de Recerca en Neurobiologia del Comportament (GReNeC), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, Barcelone, Spain.
Mérie NassarCenter for Interdisciplinary Research in Biology, Collège de France, INSERM U1050, CNRS UMR7241, Labex Memolife, Paris, France.
Laurent VenanceCenter for Interdisciplinary Research in Biology, Collège de France, INSERM U1050, CNRS UMR7241, Labex Memolife, Paris, France.
Olga ValverdeDepartament de Ciències Experimentals i de la Salut, Grup de Recerca en Neurobiologia del Comportament (GReNeC), Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Universitat Pompeu Fabra, Barcelone, Spain.
Philippe FaureINSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS - IBPS), UPMC Univ Paris 06 Sorbonne Universités, Paris, France.
Michele ZoliDipartimento di Scienze Biomediche, Metaboliche e Neuroscienze, Centro di Neuroscienze e Neurotecnologie, Università degli Studi di Modena e Reggio Emilia, Modena, Italy.
Olivier De BackerURPHYM (Unité de Recherche en Physiologie Moléculaire), NARILIS (Namur Research Institute for Life Sciences), Université de Namur, Namur, Belgium.
David GallLaboratoire de Neurophysiologie, ULB Neuroscience Institute, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Serge N SchiffmannLaboratoire de Neurophysiologie, ULB Neuroscience Institute, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Alban de Kerchove d'ExaerdeLaboratoire de Neurophysiologie, ULB Neuroscience Institute, Université Libre de Bruxelles (ULB), Brussels, Belgium adekerch@ulb.ac.be.ORCID 0000-0002-0682-5877
Université Libre de Bruxelles · BECentre National de la Recherche Scientifique · FRUniversitat Pompeu Fabra · ESUniversity of Modena and Reggio Emilia · ITUniversity of Namur · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma antigen genes (Mage) were first described as tumour markers. However, some of Mage are also expressed in healthy cells where their functions remain poorly understood. Here, we describe an unexpected role for one of these genes, Maged1, in the control of behaviours related to drug addiction. Mice lacking Maged1 are insensitive to the behavioural effects of cocaine as assessed by locomotor sensitization, conditioned place preference (CPP) and drug self-administration. Electrophysiological experiments in brain slices and conditional knockout mice demonstrate that Maged1 is critical for cortico-accumbal neurotransmission. Further, expression of Maged1 in the prefrontal cortex (PFC) and the amygdala, but not in dopaminergic or striatal and other GABAergic neurons, is necessary for cocaine-mediated behavioural sensitization, and its expression in the PFC is also required for cocaine-induced extracellular dopamine (DA) release in the nucleus accumbens (NAc). This work identifies Maged1 as a critical molecule involved in cellular processes and behaviours related to addiction.

Indexed as

AmygdalaAnimalsBehavior, AddictiveCocaineCocaine-Related DisordersDependovirusDopamineGene DeletionGlutamic AcidLocomotionMaleMiceMice, KnockoutNeoplasm ProteinsNeuronsNucleus AccumbensCocaineDopamineGlutamic AcidMaged1 protein, mouseNeoplasm Proteinsamygdaladopaminedrug sensitizationnucleus accumbensprefrontal cortex

Identifiers

PMID30002119
PMCPMC6123657
OpenAlexW2858436239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.